Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating activities:
Net (loss) income	$ (240,394,000)	$ 137,240,000	$ 4,432,000
Adjustments to net income (loss):
Goodwill impairment	236,000,000	0	0
Impairment of long-lived assets	91,904,000	0	0
Allowance for credit losses	2,058,000	2,527,000	2,599,000
Deferred tax benefit	(37,650,000)	(8,862,000)	(31,565,000)
Depreciation and amortization	38,221,000	40,268,000	86,501,000
Amortization of developed technology	14,558,000	14,558,000	14,558,000
Amortization of debt discount and issuance costs	6,087,000	10,570,000	6,857,000
Gain on debt refinancing	0	(457,000)	0
Equity-based compensation	10,349,000	14,540,000	14,982,000
Change in fair value of contingent consideration	125,000	2,964,000	(4,507,000)
Warranty provision	3,163,000	4,666,000	4,152,000
Write-down of inventories	2,923,000	6,431,000	(859,000)
Changes in operating assets and liabilities, net of business acquisition:
Accounts receivable	41,423,000	92,800,000	(76,984,000)
Inventories	(44,787,000)	66,743,000	20,870,000
Income tax receivables	(4,112,000)	9,000	5,611,000
Prepaid expenses and other	(69,708,000)	(10,840,000)	19,124,000
Accounts payable	58,180,000	(37,654,000)	12,667,000
Accrued expenses and other	(436,000)	5,325,000	1,024,000
Income tax payable	(863,000)	1,936,000	(755,000)
Lease liabilities	(8,624,000)	1,177,000	3,784,000
Deferred revenue	55,563,000	(111,986,000)	59,002,000
Net cash provided by operating activities	153,980,000	231,955,000	141,493,000
Investing activities:
Purchase of property, plant and equipment	(7,305,000)	(16,989,000)	(10,619,000)
Retirement/disposal of property, plant and equipment	34,000	168,000	0
Cash payments for the acquisition of right-of-use assets	(11,276,000)	0	0
Acquisition of STI, net of cash acquired	0	0	(373,818,000)
SAFE Investment	(3,000,000)	0	0
Sale of equity investment	11,975,000	0	0
Net cash used in investing activities	(9,572,000)	(16,821,000)	(384,437,000)
Financing activities:
Proceeds from Series A issuance	0	0	33,098,000
Proceeds from common stock issuance	0	0	15,885,000
Series A equity issuance costs	0	(1,509,000)	(1,893,000)
Tax withholding related to vesting of equity-based compensation	(1,752,000)	0	0
Common stock issuance costs	0	0	(450,000)
Dividends paid on Series A Preferred	0	0	(18,670,000)
Payments on revolving credit facility	0	0	(116,000,000)
Proceeds from revolving credit facility	0	0	116,000,000
Proceeds from issuance of other debt	93,059,000	63,311,000	20,188,000
Principal payments on term loan facility	(4,300,000)	(74,300,000)	(14,300,000)
Principal payments on other debt	(97,424,000)	(88,063,000)	(23,935,000)
Contingent consideration payments	(1,427,000)	(1,200,000)	(1,483,000)
Net cash (used in) provided by financing activities	(11,844,000)	(101,761,000)	8,440,000
Effect of exchange rate changes on cash and cash equivalent balances	(17,503,000)	1,806,000	735,000
Net change in cash and cash equivalents	115,061,000	115,179,000	(233,769,000)
Cash and cash equivalents and restricted cash, beginning of period	249,080,000	133,901,000	367,670,000
Cash and cash equivalents and restricted cash, end of period	364,141,000	249,080,000	133,901,000
Supplemental Cash Flow Information
Cash paid for interest	38,655,000	43,949,000	23,118,000
Cash paid for income taxes	27,966,000	45,942,000	10,739,000
Non-cash Investing and Financing Activities
Dividends accrued on Series A Preferred	28,160,000	26,370,000	6,389,000
Stock consideration paid for acquisition of STI	$ 0	$ 0	$ 200,224,000